Labiotech.eu

In Depth 25 Jul 2024

The future of inflammatory bowel disease treatment: what is on the horizon?

Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut.

July 25, 2024 - 8 minutesmins - By Roohi Mariam Peter

In Depth 24 Jul 2024

Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?

Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market.

July 24, 2024 - 10 minutesmins - By Willow Shah-Neville

More News! 23 Jul 2024

First AKT-targeting drug capivasertib to hit the market, could it open the door for more?

As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out!

July 23, 2024 - 7 minutesmins - By Jules Adam

Expert Advice 19 Jul 2024

The ABC of biotech partnerships

Discover eight different types of biotech partnerships, including what each one entails and its advantages and disadvantages.

July 19, 2024 - 11 minutesmins - By Willow Shah-Neville

Podcast 19 Jul 2024

Cutting through the AI hype in drug discovery

There’s certainly hype around AI, but what can it really do in drug discovery? Listen to our conversation with LabGenius to find out.

July 19, 2024

In Depth 18 Jul 2024

Lenacapavir: Can Gilead’s drug end the HIV pandemic?

Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial.

July 18, 2024 - 7 minutesmins - By Willow Shah-Neville

More News! 17 Jul 2024

Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it

Discover yet another exciting deal in biotech with Asceneuron raising $100 million to advance its Alzheimer’s candidate, ASN51.

July 17, 2024 - 10 minutesmins - By Jules Adam

KBI Biopharma microbial CLD 16JUL2024 article labiotech main illustration

How a microbial expression update is driving biotech innovation

Discover how microbial expression systems are revolutionizing protein production for next-gen therapies like antibodies and peptides.

July 16, 2024 - 7 minutesmins - By Ute Boronowsky

CatalYm’s monoclonal antibody visugromab bags $150M

News and Trends 16 Jul 2024

German biotech raises $150M on its way to tackle cancer therapy resistance

On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.

July 16, 2024 - 9 minutesmins - By Jules Adam

In Depth 15 Jul 2024

Fighting EEHV in elephants: How mRNA vaccines can offer hope against viruses affecting animals

Discover how a new mRNA vaccine could help to tackle EEHV in elephants, which is a number one killer of Asian elephant calves.

July 15, 2024 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 12 Jul 2024

Five universities in Canada to build a career in biotech in 2024

Delve into Canada’s biotech education ecosystem with five universities putting industry experience forward.

July 12, 2024 - 8 minutesmins - By Jules Adam

Podcast 12 Jul 2024

How biotechs are revolutionizing acute on-chronic liver failure?

Listen to our conversation with Genfit, a late-stage biopharma tackling acute on-chronic liver failure.

July 12, 2024

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The future of inflammatory bowel disease treatment: what is on the horizon?

Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?

First AKT-targeting drug capivasertib to hit the market, could it open the door for more?

The ABC of biotech partnerships

Cutting through the AI hype in drug discovery

Lenacapavir: Can Gilead’s drug end the HIV pandemic?

Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it

How a microbial expression update is driving biotech innovation

German biotech raises $150M on its way to tackle cancer therapy resistance

Fighting EEHV in elephants: How mRNA vaccines can offer hope against viruses affecting animals

Five universities in Canada to build a career in biotech in 2024

How biotechs are revolutionizing acute on-chronic liver failure?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!